Report Detail
Global (United States, European Union and China) Antibody Drug Conjugates (ADCs) Market Research Report 2019-2025
- RnM3636508 |
- 30 July, 2019 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.
Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.
In 2019, the market size of Antibody Drug Conjugates (ADCs) is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Antibody Drug Conjugates (ADCs).
This report studies the global market size of Antibody Drug Conjugates (ADCs), especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Antibody Drug Conjugates (ADCs) sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Astellas Pharma
Kairos Therapeutics
Market Segment by Product Type
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology
Market Segment by Application
Hospital
Clinics
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Antibody Drug Conjugates (ADCs) status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Antibody Drug Conjugates (ADCs) manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Antibody Drug Conjugates (ADCs) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Seattle Genetics Technology
- 1.3.3 ImmunoGen Technology
- 1.3.4 Immunomedics Technology
- 1.4 Market Segment by Application
- 1.4.1 Global Antibody Drug Conjugates (ADCs) Market Share by Application (2019-2025)
- 1.4.2 Hospital
- 1.4.3 Clinics
- 1.4.4 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Antibody Drug Conjugates (ADCs) Market Size
- 2.1.1 Global Antibody Drug Conjugates (ADCs) Revenue 2014-2025
- 2.1.2 Global Antibody Drug Conjugates (ADCs) Sales 2014-2025
- 2.2 Antibody Drug Conjugates (ADCs) Growth Rate by Regions
- 2.2.1 Global Antibody Drug Conjugates (ADCs) Sales by Regions 2014-2019
- 2.2.2 Global Antibody Drug Conjugates (ADCs) Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Antibody Drug Conjugates (ADCs) Sales by Manufacturers
- 3.1.1 Antibody Drug Conjugates (ADCs) Sales by Manufacturers 2014-2019
- 3.1.2 Antibody Drug Conjugates (ADCs) Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Antibody Drug Conjugates (ADCs) Revenue by Manufacturers (2014-2019)
- 3.2.2 Antibody Drug Conjugates (ADCs) Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio (CR5 and HHI)
- 3.3 Antibody Drug Conjugates (ADCs) Price by Manufacturers
- 3.4 Key Manufacturers Antibody Drug Conjugates (ADCs) Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Antibody Drug Conjugates (ADCs) Market
- 3.6 Key Manufacturers Antibody Drug Conjugates (ADCs) Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Seattle Genetics Technology Sales and Revenue (2014-2019)
- 4.1.2 ImmunoGen Technology Sales and Revenue (2014-2019)
- 4.1.3 Immunomedics Technology Sales and Revenue (2014-2019)
- 4.2 Global Antibody Drug Conjugates (ADCs) Sales Market Share by Type
- 4.3 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type
- 4.4 Antibody Drug Conjugates (ADCs) Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Antibody Drug Conjugates (ADCs) Sales by Application
6 United States
- 6.1 United States Antibody Drug Conjugates (ADCs) Breakdown Data by Company
- 6.2 United States Antibody Drug Conjugates (ADCs) Breakdown Data by Type
- 6.3 United States Antibody Drug Conjugates (ADCs) Breakdown Data by Application
7 European Union
- 7.1 European Union Antibody Drug Conjugates (ADCs) Breakdown Data by Company
- 7.2 European Union Antibody Drug Conjugates (ADCs) Breakdown Data by Type
- 7.3 European Union Antibody Drug Conjugates (ADCs) Breakdown Data by Application
8 China
- 8.1 China Antibody Drug Conjugates (ADCs) Breakdown Data by Company
- 8.2 China Antibody Drug Conjugates (ADCs) Breakdown Data by Type
- 8.3 China Antibody Drug Conjugates (ADCs) Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Antibody Drug Conjugates (ADCs) Breakdown Data by Company
- 9.2 Rest of World Antibody Drug Conjugates (ADCs) Breakdown Data by Type
- 9.3 Rest of World Antibody Drug Conjugates (ADCs) Breakdown Data by Application
- 9.4 Rest of World Antibody Drug Conjugates (ADCs) Breakdown Data by Countries
- 9.4.1 Rest of World Antibody Drug Conjugates (ADCs) Sales by Countries
- 9.4.2 Rest of World Antibody Drug Conjugates (ADCs) Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Roche
- 10.1.1 Roche Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Antibody Drug Conjugates (ADCs)
- 10.1.4 Antibody Drug Conjugates (ADCs) Product Introduction
- 10.1.5 Roche Recent Development
- 10.2 Pfizer
- 10.2.1 Pfizer Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Antibody Drug Conjugates (ADCs)
- 10.2.4 Antibody Drug Conjugates (ADCs) Product Introduction
- 10.2.5 Pfizer Recent Development
- 10.3 Novartis
- 10.3.1 Novartis Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Antibody Drug Conjugates (ADCs)
- 10.3.4 Antibody Drug Conjugates (ADCs) Product Introduction
- 10.3.5 Novartis Recent Development
- 10.4 Genmab
- 10.4.1 Genmab Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Antibody Drug Conjugates (ADCs)
- 10.4.4 Antibody Drug Conjugates (ADCs) Product Introduction
- 10.4.5 Genmab Recent Development
- 10.5 Bayer
- 10.5.1 Bayer Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Antibody Drug Conjugates (ADCs)
- 10.5.4 Antibody Drug Conjugates (ADCs) Product Introduction
- 10.5.5 Bayer Recent Development
- 10.6 Seattle Genetics
- 10.6.1 Seattle Genetics Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Antibody Drug Conjugates (ADCs)
- 10.6.4 Antibody Drug Conjugates (ADCs) Product Introduction
- 10.6.5 Seattle Genetics Recent Development
- 10.7 Takeda Pharmaceuticals
- 10.7.1 Takeda Pharmaceuticals Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Antibody Drug Conjugates (ADCs)
- 10.7.4 Antibody Drug Conjugates (ADCs) Product Introduction
- 10.7.5 Takeda Pharmaceuticals Recent Development
- 10.8 AbbVie
- 10.8.1 AbbVie Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Antibody Drug Conjugates (ADCs)
- 10.8.4 Antibody Drug Conjugates (ADCs) Product Introduction
- 10.8.5 AbbVie Recent Development
- 10.9 AbGenomics
- 10.9.1 AbGenomics Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Antibody Drug Conjugates (ADCs)
- 10.9.4 Antibody Drug Conjugates (ADCs) Product Introduction
- 10.9.5 AbGenomics Recent Development
- 10.10 ADC Therapeutics
- 10.10.1 ADC Therapeutics Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Antibody Drug Conjugates (ADCs)
- 10.10.4 Antibody Drug Conjugates (ADCs) Product Introduction
- 10.10.5 ADC Therapeutics Recent Development
- 10.11 Astellas Pharma
- 10.12 Kairos Therapeutics
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Antibody Drug Conjugates (ADCs) Sales Channels
- 11.2.2 Antibody Drug Conjugates (ADCs) Distributors
- 11.3 Antibody Drug Conjugates (ADCs) Customers
12 Market Forecast
- 12.1 Global Antibody Drug Conjugates (ADCs) Sales and Revenue Forecast 2019-2025
- 12.2 Global Antibody Drug Conjugates (ADCs) Sales Forecast by Type
- 12.3 Global Antibody Drug Conjugates (ADCs) Sales Forecast by Application
- 12.4 Antibody Drug Conjugates (ADCs) Forecast by Regions
- 12.4.1 Global Antibody Drug Conjugates (ADCs) Sales Forecast by Regions 2019-2025
- 12.4.2 Global Antibody Drug Conjugates (ADCs) Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Antibody Drug Conjugates (ADCs). Industry analysis & Market Report on Antibody Drug Conjugates (ADCs) is a syndicated market report, published as Global (United States, European Union and China) Antibody Drug Conjugates (ADCs) Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Antibody Drug Conjugates (ADCs) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
